Last reviewed · How we verify

NCT07202234

Bacteriophage Cocktail Therapy for Multidrug-Resistant Gram-Negative Ventilator-Associated Pneumonia

Not yet recruiting NA Last updated 1 October 2025
What this trial tests

NA trial testing Phage cocktail administered via nebulization in VAP - Ventilator Associated Pneumonia in 248 participants. Not yet recruiting.

Timeline
1 November 2025
Primary endpoint
31 May 2028
31 May 2028

Quick facts

Lead sponsorChinese PLA General Hospital
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment248
Start date1 November 2025
Primary completion31 May 2028
Estimated completion31 May 2028

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 85, any sex, with VAP - Ventilator Associated Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to systematically evaluate the efficacy and safety of bacteriophage cocktail therapy in patients with ventilator-associated pneumonia caused by Gram-negative bacterial infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for VAP - Ventilator Associated Pneumonia

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07202234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing